Graham Beaton
YOU?
Author Swipe
View article: Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models Open
Background: NASH causes a tremendous health care burden in the United States. A glucagon-like peptide-1 agonist, semaglutide (Sema), treatment resulted in hepatic steatosis reduction in clinical trials of NASH. Lysophosphatidic acid recept…
View article: Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model
Drug-Eluting Embolic Loaded with Tyrosine Kinase Inhibitor Targeted Therapies for Transarterial Chemoembolization in a VX2 Model Open
Drug-eluting embolic transarterial chemoembolization (DEE-TACE) improves the overall survival of hepatocellular carcinoma (HCC), but the agents used are not tailored to HCC. Our patented liposomal formulation enables the loading and elutio…
View article: Reduced AIBP expression in bronchial epithelial cells of asthmatic patients: Potential therapeutic target
Reduced AIBP expression in bronchial epithelial cells of asthmatic patients: Potential therapeutic target Open
YIM is an inventor listed in patent applications related to the topic of this paper and scientific founder of Raft Pharmaceuticals LLC. The terms of this arrangement have been reviewed and approved by the University of California, San Dieg…
View article: Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain
Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain Open
Neuroinflammation is a major component in the transition to and perpetuation of neuropathic pain states. Spinal neuroinflammation involves activation of TLR4, localized to enlarged, cholesterol-enriched lipid rafts, designated here as infl…
View article: Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM
Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM Open
Background: Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) is a pro-mitotic transcription factor highly expressed in glioma stem cells (GSCs) that has been shown to be essential for tumorigenesis and a significant driver of tumor g…
View article: Targeting toll-like receptor-4 (TLR4)—an emerging therapeutic target for persistent pain states
Targeting toll-like receptor-4 (TLR4)—an emerging therapeutic target for persistent pain states Open
Toll-like receptors (TLRs) are a family of pattern recognition receptors that initiate signaling in innate and adaptive immune pathways. The highly conserved family of transmembrane proteins comprises an extracellular domain that recognize…
View article: HGG-01. RADIATION INCREASES PRE-CLINICAL EFFICACY OF OLIG2 INHIBITOR CT-179 IN PEDIATRIC GBM
HGG-01. RADIATION INCREASES PRE-CLINICAL EFFICACY OF OLIG2 INHIBITOR CT-179 IN PEDIATRIC GBM Open
BACKGROUND: Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) is a pro-mitotic transcription factor highly expressed in glioma stem cells. We evaluated the pre-clinical efficacy of the OLIG2 inhibitor CT-179 in patient-derived orthoto…
View article: EXTH-18. CT-179 SELECTIVELY TARGETS OLIG2-POSITIVE GLIOMA STEM CELLS AND DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA
EXTH-18. CT-179 SELECTIVELY TARGETS OLIG2-POSITIVE GLIOMA STEM CELLS AND DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA Open
Olig2 is a lineage-specific bHLH transcription factor in normal brain development and has been shown to be a critical oncogene controlling the tumorigenesis, growth, invasion, differentiation and radiation resistance of gliomas, including …
View article: P08.21 Discovery of CT-179--a small molecule inhibitor of the transcription factor OLIG2 with potent anti-tumour activity in high-grade glioma
P08.21 Discovery of CT-179--a small molecule inhibitor of the transcription factor OLIG2 with potent anti-tumour activity in high-grade glioma Open
OLIG2 is a protein transcription factor that is expressed exclusively in progenitor cells in the brain and spinal cord during development. Typically, OLIG2 is not active in the adult brain and is not found outside the central nervous syste…
View article: EXTH-08. NOVEL OLIG2 INHIBITOR DEMONSTRATES PRE-CLINICAL EFFICACY IN PEDIATRIC GBM
EXTH-08. NOVEL OLIG2 INHIBITOR DEMONSTRATES PRE-CLINICAL EFFICACY IN PEDIATRIC GBM Open
Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) is pro-mitotic, expressed almost exclusively in the central nervous system (CNS), and is highly expressed in gliomas. We evaluated the in vitro and in vivo efficacy of CT-179, an OLIG2…